Dana-Farber Cancer Institute: Lymphoma trials

The registry lists 27 Lymphoma studies with Dana-Farber Cancer Institute as lead sponsor. 4 are open to participants now and 7 have results posted.

Early Phase 1 1Phase 1 7Phase 2 9Phase 3 1Phase 4 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingNCT07426484Phase 4
• Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialRecruitingNCT06923397Not applicable
• HEME Home Transfusion ProgramRecruitingNCT06487247Not applicable
• Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLRecruitingNCT06475235Phase 1
• Rituximab + Immunotherapy in Follicular LymphomaTerminatedNCT03636503Phase 1Results posted
• Pembrolizumab in Neoplasms or LymphomasSuspendedNCT03316573Phase 2Results posted
• A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin LymphomaCompletedNCT02919670Not applicableResults posted
• CHOEP + High Dose Therapy + Auto SCT for T-Cell LymphomaTerminatedNCT01746173Phase 2Results posted
• Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With LymphomaCompletedNCT00928018Phase 3Results posted
• Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's LymphomaCompletedNCT00684411Phase 2Results posted
• Intensive Chemotherapy and Rituximab in the Treatment of Burkitt LymphomaTerminatedNCT00126191Phase 2Results posted
• UPLYFT For Lymphoma SurvivorsCompletedNCT05080166Not applicable
• Axi-cel in CNS LymphomaActive, not recruitingNCT04608487Phase 1
• ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesWithdrawnNCT04043845Phase 1
• Cyclophosphamide and Alemtuzumab In LymphomaTerminatedNCT03132584Phase 1
• Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaCompletedNCT02909777Phase 1
• A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell LymphomaTerminatedNCT01878708Early Phase 1
• SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)CompletedNCT01402687
• Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD MethotrexateCompletedNCT01319591
• Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related DisordersActive, not recruitingNCT01177527
• Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical TrialsCompletedNCT00487513
• Ph II CHOP+Velcade in Mediastinal LBCLTerminatedNCT00361621Phase 2
• Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular LymphomaCompletedNCT00251394Phase 2
• Phase II Study of Campath-1H Antibody to Treat Waldenstrom's MacroglobulinemiaCompletedNCT00142181Phase 2
• Amifostine for Head and Neck Irradiation in LymphomaCompletedNCT00136474Phase 2
• Chemotherapy Followed by Zevalin for Relapsed Mantle Cell LymphomaCompletedNCT00119730Phase 2
• Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous TherapyCompletedNCT00005988Phase 1